Regarding cancer risk, during a median follow-up of 4.0 years, the incidence of cancers (excluding nonmelanoma skin cancer) was higher with the combined tofacitinib doses compared to a TNF inhibitor, with lung cancer being the most common cancer described in the tofacitinib group. The gene discussed is TNF; the disease is cancer.